Chinese patent analysis of multi-target tyrosine kinase inhibitor regorafenib
HONG Meng-shi
LI You
Abstract：Molecular targeted therapy has become a research hotspot in the field of cancer therapy in recent years.Regorafenib belongs to the multi-target tyrosine kinase inhibitor class of antitumor drug developed by Bayer company,which was approved by NMPA in March 2017.This article introduces the status of regorafenib-related Chinese patent applications and focuses on combing and analyzing the development context of patent technology,in order to provide reference for the drug R&D and patent portfolio for relevant domestic pharmaceutical companies.
Keywords：regorafenibtyrosine kinasetumorpatent portfoliopatent analysis
Publication Date：2023-12-15
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：9( 2385-2393 )